
Understanding the Side Effects of RLY-2608 in HR+, HER2– Breast Cancer
Investigators evaluated the updated efficacy of treatment with RLY-2608, a mutant-selective PI3Kα inhibitor, when combined with Faslodex (fulvestrant) for patients with PIK3CA-mutant hormone receptor (HR)-positive, HER2-negative advanced breast cancer …